Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial

OBJECTIVE: Low‐dose methotrexate (LD‐MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia, leukopenia, and skin cancers, but the risks of myelosuppression and malignancy during LD‐MTX use remain incompletely described. We examined the...

Full description

Saved in:
Bibliographic Details
Published in:ACR Open Rheumatol
Main Authors: Vanni, Kathleen M.M., Berliner, Nancy, Paynter, Nina P., Glynn, Robert J., MacFadyen, Jean, Colls, Joshua, Lu, Fengxin, Xu, Chang, Ridker, Paul M., Solomon, Daniel H.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7738806/
https://ncbi.nlm.nih.gov/pubmed/33201596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr2.11187
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items